Clinical trials: Tislelizumab
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma
This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of CD19/22 CART cells combined with PD-1 Inhibitor in relapsed/refractory B Cell Lymphoma.
- Trial name
- NCT04539444
- Testing
- CD19/22 CART, Tislelizumab
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The First Affiliated Hospital of Soochow University
High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study
This is a phase II study to determine the safety and efficacy of tislelizumab when given in combination with nab-paclitaxel as treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) which is not…
- Trial name
- NCT05418309
- Testing
- Tislelizumab Nab paclitaxel
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Tianjin Medical University Second Hospital
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression
The efficacy and safety of combination with Disitamab Vedotin and with Tislelizumab and Capecitabine for perioperative treatment of locally advanced gastric cancer with HER2 overexpression.
- Trial name
- NCT06560528
- Testing
- combination with Disitamab Vedotin and with Tislelizumab and Capecitabine
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Solid Tumor
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
This is a Phase 1 study to evaluate the safety, tolerability, PK, and preliminary efficacy of IO-108 monotherapy and in combination with anti-PD-1 monoclonal antibody pembrolizumab or tislelizumab in adult patients with advanced…
- Trial name
- NCT05508100
- Testing
- IO-108, IO-108 + pembrolizumab, IO-108 + tislelizumab
- Where
- 14 sites in China
- Volunteers
- 38 people
- Sponsor
- Immune-Onc Therapeutics
Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL
Aim of this study will evaluate the efficacy and safety of tislelizumab in combination with lenalidomide in in patients with relapsed or refractory Elderly Patients with non-GCB Diffuse Large B Cell Lymphoma
- Conditions
- Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb, Transformed Lymphoma
- Trial name
- NCT04796857
- Testing
- PD-1 Antibody, Lenalidomide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huiqiang Huang
Extensive Stage Lung Small Cell Cancer
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
This is an open-label umbrella study conducted in first treatment ES-SCLC patients, employing a novel umbrella trial design (biomarker-integrated multi-arm trial with a shared ICI+chemotherapy control arm).
- Trial name
- NCT07172412
- Testing
- Selinexor, Anlotinib, DLL3 CAR-NK cells
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
HCC, Precision Therapy
Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models
Surgery is the main curative treatment for hepatocellular carcinoma(HCC) patients, but 70%-80% of HCC patients are in the middle and advanced stages at the time of diagnosis and cannot be surgically resected.
- Trial name
- NCT06463444
- Testing
- HAIC + Tislelizumab +lenvatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chen Xiaoping
Lymphoma
Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type
This clinical trial intends to analyze the efficacy of PD-1 inhibitor combined with radiotherapy for newly diagnosed NK/T-cell lymphoma. The investigational product in this clinical trial is tislelizumab, a PD-1 inhibitor.
- Trial name
- NCT05477264
- Testing
- Tislelizumab
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Won Seog Kim
Rectal Neoplasms
Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer
Rectal cancer is one of the common malignant tumors of the digestive tract. Some patients with rectal cancer are already advanced tumors when they are first diagnosed.
- Trial name
- NECI (NCT05420584)
- Testing
- Arterial chemoembolization, Tislelizumab Injection, XELOX
- Where
- China
- Volunteers
- 83 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Biliary Tract Cancer
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
This is a multicenter, non-randomized, umbrella, open-label phase II clinical study, aiming to observe and evaluate, as well as explore the efficacy and safety of precision targeted therapy based on NGS technology for…
- Trial name
- NCT07282262
- Testing
- Ivosidenib, Lenvatinib, PD-1/PD-L1 inhibitor
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Recurrent or Metastatic Nasopharyngeal Cancer
Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
This study was designed to compare the efficacy and safety of tislelizumab (BGB-A317) combined with gemcitabine plus cisplatin versus placebo combined with gemcitabine plus cisplatin as first-line treatment for recurrent or…
- Trial name
- RATIONALE-309 (NCT03924986)
- Testing
- Tislelizumab, Gemcitabine, Cisplatin
- Where
- 37 sites in China, Taiwan and 1 more
- Volunteers
- 263 people
- Sponsor
- BeiGene
NSCLC, Tislelizumab
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study
In clinical practice, some patients cannot tolerate concurrent chemoradiotherapy. The purpose of this study is to observe the efficacy and safety of Tislelizumab combined with platinum-based doublet chemotherapy followed by…
- Conditions
- NSCLC, Tislelizumab, Chemotherapy, Hypofractionated Radiotherapy
- Trial name
- NCT07085182
- Testing
- SBRT combined with Tislelizumab followed by Tislelizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zibo Municipal Hospital
Esophageal Squamous Cell Carcinoma
Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
The study aimed to evaluate the efficacy and safety of sitravatinib in combination with tislelizumab as a second- or third-line treatment for participants with locally advanced, unresectable, or metastatic esophageal squamous…
- Trial name
- NCT05461794
- Testing
- Sitravatinib, Tislelizumab, Docetaxel
- Where
- 31 sites in China
- Volunteers
- 96 people
- Sponsor
- BeiGene
Hepatocellular Carcinoma (HCC)
Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
This study investigated the efficacy, safety, and pharmacokinetics of the anti-PD-1 monoclonal antibody BGB-A317 in participants with previously treated hepatocellular unresectable carcinoma.
- Trial name
- NCT03419897
- Testing
- Tislelizumab
- Where
- 54 sites in China, France and 6 more
- Volunteers
- 249 people
- Sponsor
- BeiGene
Nasopharyngeal Carcinoma
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
This study aims to explore the efficacy and adverse events of reduced-dose radiotherapy (40.2Gy) versus conventional-dose radiotherapy (49.2Gy) to low-risk target volume for chemosensitive intermediate-stage nasopharyngeal…
- Trial name
- NCT07328854
- Testing
- Cisplatin-based induction chemotherapy, Full course of PD-1 monoclonal antibody, Reduced-dose radiotherapy to CTV2
- Where
- 15 sites in China
- Volunteers
- 346 people
- Sponsor
- Ming-Yuan Chen
Ovary Cancer
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer
The R0 resection rate in neoadjuvant chemotherapy for advanced ovarian cancer remains below 50%, indicating unmet clinical needs.
- Trial name
- NCT07667751
- Testing
- Sunitinib、Olaparib、Tolilizumab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Bai-Rong Xia
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced…
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
- Trial name
- KontRASt-01 (NCT04699188)
- Testing
- JDQ443, TNO155, tislelizumab
- Where
- 38 sites in United States, Australia and 14 more
- Volunteers
- 344 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Neoplasms
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer
It is a single-center, retrospective, controlled study to investigate the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin for locally advanced mid-low rectal cancer.
- Trial name
- NCT06024356
- Testing
- Thymalfasin
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Beijing Friendship Hospital
Hepatocellulcar Carcinoma
Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line
Although immunotherapy-based therapies (including targeted-immunotherapy or dual-immunotherapy protocols) have become the first-line standard treatment for advanced hepatocellular carcinoma (HCC), there remains a lack of…
- Trial name
- NCT07501351
- Testing
- Intensified Therapy, Conversion Therapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
Triple Negative Breast Cancer
Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer
The primary scientific question of interest of this study is whether the combination of ociperlimab, tislelizumab and chemotherapy improves progression-free survival (PFS) compared to the combination of placebo, pembrolizumab and…
- Trial name
- AdvanTIG-211 (NCT05809895)
- Testing
- Ociperlimab, Tislelizumab, Paclitaxel
- Sponsor
- Novartis Pharmaceuticals